Breast Cancer Coverage from Every Angle

Javier Cortes, MD, PhD, on Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer

Posted: Thursday, January 2, 2020

Javier Cortes, MD, PhD, of the IOB Institute of Oncology, talks about whether checkpoint inhibitor treatment is going to be a feasible option for some breast cancer patients, and whether this class of drugs is easier for patients to tolerate, in general, than single-agent cytotoxic regimens.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.